drugset / Trial / NCT07316608

A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults

NCT07316608

Phase 1 Completed 44 enrolled AstraZeneca Parexel · collab
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to assess how well laroprovstat and rosuvastatin combined in a single tablet to be taken by mouth works compared with laroprovstat and rosuvastatin individual tablets taken by mouth (relative bioavailability) in healthy adults.

Timeline

Start
2026-03-16
Primary completion
2026-06-05
Completion
2026-06-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Laroprovstat Small molecule Oral
Subject Rosuvastatin Small molecule Oral

Indications

No indication recorded.